| Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab RW Joseph, J Elassaiss-Schaap, R Kefford, WJ Hwu, JD Wolchok, ... Clinical Cancer Research 24 (20), 4960-4967, 2018 | 263 | 2018 |
| Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice L Bueno, DP de Alwis, C Pitou, J Yingling, M Lahn, S Glatt, IF Trocóniz European journal of cancer 44 (1), 142-150, 2008 | 242 | 2008 |
| Evaluation of dosing strategy for pembrolizumab for oncology indications T Freshwater, A Kondic, M Ahamadi, CH Li, R de Greef, D de Alwis, ... Journal for immunotherapy of cancer 5, 1-9, 2017 | 230 | 2017 |
| Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation JY Chien, S Friedrich, MA Heathman, DP de Alwis, V Sinha The AAPS journal 7, E544-E559, 2005 | 204 | 2005 |
| Considerations in the design and development of transport inhibitors as adjuncts to drug therapy AH Dantzig, DP de Alwis, M Burgess Advanced drug delivery reviews 55 (1), 133-150, 2003 | 181 | 2003 |
| Pembrolizumab exposure–response assessments challenged by association of cancer cachexia and catabolic clearance DC Turner, AG Kondic, KM Anderson, AG Robinson, EB Garon, JW Riess, ... Clinical Cancer Research 24 (23), 5841-5849, 2018 | 171 | 2018 |
| Model‐based characterization of the pharmacokinetics of pembrolizumab: a humanized anti–PD‐1 monoclonal antibody in advanced solid tumors M Ahamadi, T Freshwater, M Prohn, CH Li, DP De Alwis, R De Greef, ... CPT: pharmacometrics & systems pharmacology 6 (1), 49-57, 2017 | 157 | 2017 |
| Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer M Chatterjee, DC Turner, E Felip, H Lena, F Cappuzzo, L Horn, EB Garon, ... Annals of Oncology 27 (7), 1291-1298, 2016 | 149 | 2016 |
| A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with … A Sandler, M Gordon, DP De Alwis, I Pouliquen, L Green, P Marder, ... Clinical cancer research 10 (10), 3265-3272, 2004 | 144 | 2004 |
| A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation M Lala, TR Li, DP de Alwis, V Sinha, K Mayawala, N Yamamoto, LL Siu, ... European Journal of Cancer 131, 68-75, 2020 | 128 | 2020 |
| Optimal dosing for targeted therapies in oncology: drug development cases leading by example JR Sachs, K Mayawala, S Gadamsetty, SP Kang, DP de Alwis Clinical Cancer Research 22 (6), 1318-1324, 2016 | 127 | 2016 |
| Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose‐range selection of the anti–PD‐1 antibody pembrolizumab A Lindauer, CR Valiathan, K Mehta, V Sriram, R De Greef, ... CPT: pharmacometrics & systems pharmacology 6 (1), 11-20, 2017 | 119 | 2017 |
| A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with … EH Rubin, DP De Alwis, I Pouliquen, L Green, P Marder, Y Lin, R Musanti, ... Clinical cancer research 8 (12), 3710-3717, 2002 | 110 | 2002 |
| Using model‐based “learn and confirm” to reveal the pharmacokinetics‐pharmacodynamics relationship of pembrolizumab in the KEYNOTE‐001 Trial J Elassaiss‐Schaap, S Rossenu, A Lindauer, SP Kang, R De Greef, ... CPT: pharmacometrics & systems pharmacology 6 (1), 21-28, 2017 | 99 | 2017 |
| Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic SP Kang, K Gergich, GM Lubiniecki, DP de Alwis, C Chen, MAB Tice, ... Annals of Oncology 28 (6), 1388-1398, 2017 | 93 | 2017 |
| Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies PM Fracasso, LJ Goldstein, DP de Alwis, JS Rader, MA Arquette, ... Clinical cancer research 10 (21), 7220-7228, 2004 | 93 | 2004 |
| Implementation of quantitative and systems pharmacology in large pharma SAG Visser, DP De Alwis, T Kerbusch, JA Stone, SRB Allerheiligen CPT: pharmacometrics & systems pharmacology 3 (10), 1-10, 2014 | 86 | 2014 |
| Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab‐treated advanced melanoma MS Chatterjee, J Elassaiss‐Schaap, A Lindauer, DC Turner, A Sostelly, ... CPT: pharmacometrics & systems pharmacology 6 (1), 29-39, 2017 | 81 | 2017 |
| A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979) S Callies, DP De Alwis, JG Wright, A Sandler, M Burgess, L Aarons Cancer chemotherapy and pharmacology 51, 107-118, 2003 | 64 | 2003 |
| Rendering the 3+ 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy L Nie, EH Rubin, N Mehrotra, J Pinheiro, LL Fernandes, A Roy, S Bailey, ... Clinical Cancer Research 22 (11), 2623-2629, 2016 | 61 | 2016 |
